We have identified that the ratio of neutrophils to lymphocytes from a simple full blood count can identify malignant mesothelioma patients with good or poor prognoses with a survival difference of almost 10 months. This finding will alter the management of this condition and the test can be performed inexpensively anywhere in the world. These data also highlight the importance of the inflammatory response in influencing cancer prognosis and emphasise that this should be an important focus of cancer research in the future.
INTRODUCTION
Malignant mesothelioma (MM) is an aggressive, asbestos-related neoplasm that arises from the mesothelium, a membrane lining the serosal cavities (1) .
Previously rare, MM is increasing in incidence in developed countries (2) , but due to the continued widespread use of asbestos in developing countries (3), MM will remain a worldwide health issue in the ensuing decades.
Furthermore, MM remains an invariably fatal disease, with a median survival ranging from 7 months to 2 years depending on the stage of the disease and modalities of treatments used (4) (5) (6) .
Despite a very poor overall prognosis for patients with MM, some patients live with their disease for a considerable time. Currently, two composite scoring systems devised by the European Organisation for Research and Treatment of Cancer (EORTC) and the Cancer and Leukemia Group B (CALGB) are used to predict outcomes for MM patients. The EORTC found that performance status, white cell count (WCC), gender, histological subtype and whether the histological diagnosis was definitive or not, were significant prognostic factors. Based on these variables, they were able to stratify patients into either good (1 year survival rate of 40%) or poor prognosis groups (1 year survival rate of 12%) (7) . The CALGB used exponential survival tree analysis with prognostic variables of performance status, age, WCC, haemoglobin, presence or absence of weight loss and chest pain and defined 6 groups of patients with varying median survival times ranging from 1.4 to 13.9 months (8) . However, these systems are not used routinely because they are relatively unwieldy and thus, their use is largely confined to the clinical trial setting to stratify patient cohorts so that treatment results can be appropriately interpreted and compared. An easily reproducible and inexpensive marker that could better estimate the prognosis of patients with MM would be of substantial value for clinicians involved in treatment of MM and for determining appropriate levels of compensation for those who developed MM after occupational asbestos exposure.
Inflammation appears to play a critical role in the development and progression of numerous cancers, including MM. A variety of infectious agents and environmental toxins produce the chronic tissue damage that leads to the local inflammatory reactions in these malignancies, with asbestos fibres the principal issue in MM. Tumour development and progression induced by an inflammatory response is thought to be mediated by an interaction between pro-inflammatory cytokines and pathways including NF-κB and STAT3 (9) . In addition to promoting tumour growth, the release of pro-inflammatory cytokines can produce systemic inflammatory symptoms such as fever, sweats and weight loss and result in the release of acute phase proteins from the liver that can be measured in plasma.
It has been postulated that markers of systemic inflammation may provide useful information for prognostication. Various markers of systemic inflammatory response, including cytokines, C-reactive protein (CRP),
Research. 
MATERIALS AND METHODS

Study Patients
Consecutive MM patients who had been commenced on chemotherapy from The analysis of IL-6, IL-6 SR, and VEGF in the phase II thalidomide trial was carried out using the enzyme-linked immunosorbent assay (ELISA) method.
Research. As there is no defined cut-off value for these parameters, the median value was chosen a priori to categorise patients into high and low groups.
Statistical Analysis
Overall 
RESULTS
Patient Demographics and Outcomes
A total of 173 patients were included. One hundred and nineteen patients participated in the first line therapy protocols, while 54 patients had previous treatments. (Table 1 ) At the time of this report, 76% of patients were deceased. Among those who were still alive (n=42), the median follow up was 9.8 months (range: 0.8 months to 82.1 months).
Baseline characteristics of the patient groups included in this study are given in Figure 2b shows the survival curves according to NLR.
In patients receiving second or third line treatment, epithelioid histological subtype and NLR <5 were associated with longer survival (p=0.047 and 0.025 respectively). In multivariate analysis, only NLR<5 (HR 2.1; 95% CI, 1.1-3.9; p=0.028) was an independent predictor of length of survival. Figure 2c shows the survival curves according to NLR in the previously-treated group (median OS: 10.4 vs. 3.8 months for NLR<5 and ≥5 respectively; p=0.025).
Normalisation of NLR after 1 Cycle of Systemic Therapy (Subgroup
Analysis)
A total of 65 patients were included in this subgroup analysis. (Figure 1 )
Twenty eight patients (43%) showed a normalisation of NLR after 1 cycle of systemic therapy. Figure 2d shows that a normalisation of NLR was associated with longer survival compared to patients with persistently abnormal NLR (median OS: 7.8 vs. 5.0 months for patients with normalised NLR and persistently abnormal NLR, respectively; p=0.034).
Symptoms, Cytokines, and NLR
An exploratory analysis in 63 thalidomide patients, suggested that NLR is not 
DISCUSSION
The results from this study confirm our hypothesis and suggest that an elevated NLR is an independent predictor for poor survival in MM patients undergoing systemic therapy, regardless of whether this is given as an initial or subsequent therapy. This result is in accordance with previous observations on the association between NLR and a variety of cancers such as lung cancer, colorectal cancer and patients with resected intrahepatic cholangiocarcinoma (13) (14) (15) (16) 19 ). In our current retrospective series of MM We acknowledge that our findings require validation using an independent series of patients with standardised treatment, although such cohorts may be difficult to access and chemotherapy studies have previously not routinely collected lymphocyte counts.
Research. Our study results support that inflammatory processes may be appropriate targets for interventions aimed at improving survival in this highly symptomatic condition. Given the prevalence of the elevated NLR in MM and its associated poor prognosis, one could think of evaluating the efficacy of specific (antibodies to TNF-α and IL-6) and non-specific anti-inflammatory interventions in an attempt to improve outcomes.
Some studies have suggested that tumour stage is an important prognostic factor in MM (6, 12, 20) . In our series, clinical stage was not a positive predictor for prognosis. This may be attributed to the substantial amount of missing staging data and a consequent small number of patients with early stage disease (n=6). We also examined the EORTC prognostic scoring system. Our results confirmed that the EORTC score provides useful prognostic information, but in multivariate analysis, the EORTC prognostic score did not remain an independent prognostic factor.
One other limitation of our study was the inability to include the CALGB prognostic score as a prognostic variable due to incomplete clinical information (i.e. clinical symptoms of weight loss and chest pain). As such the prognostic role of NLR could not be directly compared to this prognostic index. Such correlations should be undertaken in future analyses.
In conclusion, we found that an NLR<5 was an independent predictor of longer survival for patients with MM undergoing systemic therapy. MM
Research. Chemotherapy-naïve n=119
Previously-treated n=54
Baseline Full Blood Count n=115
Baseline Full Blood Count n=54
Normal NLR (<5) n=62
Normal NLR (<5) n=33
Elevated NLR (≥5) n=53
Elevated NLR (≥5) n=20 
